Effectiveness of a dedicated small bowel neoplasia screening program by capsule endoscopy in Lynch syndrome: 5 years results from a tertiary care center.

Lynch syndrome capsule endoscopy diagnostic yield smal bowel neoplasia screening

Journal

Therapeutic advances in gastroenterology
ISSN: 1756-283X
Titre abrégé: Therap Adv Gastroenterol
Pays: England
ID NLM: 101478893

Informations de publication

Date de publication:
2020
Historique:
received: 04 12 2019
accepted: 11 05 2020
entrez: 11 8 2020
pubmed: 11 8 2020
medline: 11 8 2020
Statut: epublish

Résumé

The role of small bowel neoplasia (SBN) screening in asymptomatic patients with Lynch syndrome (LS) is uncertain. The aim of our study was to assess the effectiveness of screening by capsule endoscopy (CE) in these patients. This study was an observational, analytical, and retrospective single-center study within the PRED-IdF network. All consecutive asymptomatic patients older than 35 years-old with confirmed LS and no personal history of SBN who started the screening from 2010-2015 were included. The baseline screening and 24 months follow-up were performed by CE. The CE diagnostic yield (positive tumor or polyp) and accuracy, using the follow-up as gold standard, were evaluated. A total of 150 patients underwent the SBN screening program and 135 (52.7 ± 11.2 years-old, 37.8% male) met the inclusion criteria. The baseline CE diagnostic yield was 4.4% (3 polyps, 3 tumors) and the proximal small bowel was the most common location ( CE is an accurate procedure for baseline screening of SBN in LS patients and may be efficient for follow-up procedures. However, the optimal starting age of screening and intervals of follow-up must be clarified.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
The role of small bowel neoplasia (SBN) screening in asymptomatic patients with Lynch syndrome (LS) is uncertain. The aim of our study was to assess the effectiveness of screening by capsule endoscopy (CE) in these patients.
METHODS METHODS
This study was an observational, analytical, and retrospective single-center study within the PRED-IdF network. All consecutive asymptomatic patients older than 35 years-old with confirmed LS and no personal history of SBN who started the screening from 2010-2015 were included. The baseline screening and 24 months follow-up were performed by CE. The CE diagnostic yield (positive tumor or polyp) and accuracy, using the follow-up as gold standard, were evaluated.
RESULTS RESULTS
A total of 150 patients underwent the SBN screening program and 135 (52.7 ± 11.2 years-old, 37.8% male) met the inclusion criteria. The baseline CE diagnostic yield was 4.4% (3 polyps, 3 tumors) and the proximal small bowel was the most common location (
CONCLUSIONS CONCLUSIONS
CE is an accurate procedure for baseline screening of SBN in LS patients and may be efficient for follow-up procedures. However, the optimal starting age of screening and intervals of follow-up must be clarified.

Identifiants

pubmed: 32774463
doi: 10.1177/1756284820934314
pii: 10.1177_1756284820934314
pmc: PMC7391432
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1756284820934314

Informations de copyright

© The Author(s), 2020.

Déclaration de conflit d'intérêts

Conflict of interest statement: The authors declare that there is no conflict of interest.

Références

Endoscopy. 2010 Dec;42(12):1057-62
pubmed: 20821360
World J Gastrointest Endosc. 2015 Jun 10;7(6):652-8
pubmed: 26078833
Dig Liver Dis. 2019 Feb;51(2):299-303
pubmed: 30448460
Gut. 2007 Sep;56(9):1198-201
pubmed: 17409122
Lancet Oncol. 2012 Jun;13(6):598-606
pubmed: 22552011
World J Gastrointest Endosc. 2013 May 16;5(5):219-25
pubmed: 23678374
Endoscopy. 2019 Nov;51(11):1082-1093
pubmed: 31597170
Clin Gastroenterol Hepatol. 2011 Apr;9(4):340-3
pubmed: 21070872
Am J Gastroenterol. 2014 Aug;109(8):1159-79
pubmed: 25070057
Radiology. 2010 Mar;254(3):765-73
pubmed: 20177091
Cancer. 1998 Jul 15;83(2):240-4
pubmed: 9669805
Endoscopy. 2008 Jun;40(6):488-95
pubmed: 18464193
Genet Med. 2020 Jan;22(1):15-25
pubmed: 31337882
Gastroenterology. 2005 Mar;128(3):590-9
pubmed: 15765394
Endoscopy. 2019 Sep;51(9):877-895
pubmed: 31342472
Lancet Oncol. 2008 Sep;9(9):901-5
pubmed: 18760246
J Pediatr Gastroenterol Nutr. 2019 Mar;68(3):442-452
pubmed: 30585892
Endoscopy. 2004 Dec;36(12):1054-9
pubmed: 15578294
Endosc Int Open. 2017 Jul;5(7):E622-E626
pubmed: 28691043
Best Pract Res Clin Gastroenterol. 2012 Jun;26(3):359-68
pubmed: 22704577
Rev Esp Enferm Dig. 2015 Jul;107(8):495-500
pubmed: 26228953
Gut. 2015 Oct;64(10):1578-83
pubmed: 25209657
JAMA. 2011 Jun 8;305(22):2304-10
pubmed: 21642682
J Gastroenterol Hepatol. 2010 Jun;25(6):1079-86
pubmed: 20594222

Auteurs

Guillaume Perrod (G)

Gastroenterology and Endoscopy Unit, Georges Pompidou European Hospital, 20 Rue Leblanc, Paris, 75015, France.

Elia Samaha (E)

Gastroenterology and Endoscopy Unit, Georges Pompidou European Hospital, Paris, France.

Enrique Perez-Cuadrado-Robles (E)

Gastroenterology and Endoscopy Unit, Georges Pompidou European Hospital, Paris, France.

Arthur Berger (A)

Gastroenterology and Endoscopy Unit, Georges Pompidou European Hospital, Paris, France.

Hedi Benosman (H)

Gastroenterology and Endoscopy Unit, Georges Pompidou European Hospital, Paris, France.

Sherine Khater (S)

Gastroenterology and Endoscopy Unit, Georges Pompidou European Hospital, Paris, France.

Ariane Vienne (A)

Gastroenterology and Endoscopy Unit, Georges Pompidou European Hospital, Paris, France.

Charles-André Cuenod (CA)

Radiology Unit, Georges Pompidou European Hospital, Paris, France.

Aziz Zaanan (A)

Oncogenetic department, Georges Pompidou European Hospital, Paris, France.

Pierre Laurent-Puig (P)

Oncogenetic department, Georges Pompidou European Hospital, Paris, France.

Gabriel Rahmi (G)

Gastroenterology and Endoscopy Unit, Georges Pompidou European Hospital, Paris, France.

Christophe Cellier (C)

Gastroenterology and Endoscopy Unit, Georges Pompidou European Hospital, Paris, France.

Classifications MeSH